



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Alan D. Snow et al.                      Art Unit : 1617  
Serial No. : 10/077,596                                  Examiner : Jiang, Shaojia A  
Filed : February 15, 2002  
Title : PROANTHOCYANIDINS FOR THE TREATMENT OF AMYLOID AND  
ALPHA-SYNUCLEIN DISEASE

**INFORMATION DISCLOSURE STATEMENT**  
**IN ACCORDANCE WITH 37 C.F.R. 1.97-1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Because this Information Disclosure Statement is filed after the receipt of a First Office Action on the Merits for the above-captioned application, a check for the filing fee of \$180.00 is enclosed. If no proper payment is enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 06-1050.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Form PTO-1449 (8 pages) and some hard copies of the references are provided herewith in connection with the above-captioned application. In accordance with 37 C.F.R. §1.98(d), copies of the references listed on the Form PTO-1449 marked with a double asterisk \*\*, in the "Examiner Initial" column, are not provided herewith as they have been previously provided in connection with U.S. Serial Nos. 09/938,987, which are relied upon for an earlier filing date in accordance with 35 U.S.C. §120.

The documents cited on the Forms PTO-1449 are in the English language, with the exception of Items AD and AE. Items AD and AE (Japanese patent No. JP 10-245342 and 1-151514 respectively) are in the Japanese language and are supplied with an English language Japanese Patent and Derwent Abstracts (Items DS and BM respectively). Also provided is the English language translation of Japanese patent No. JP 10-245342, Item FB. Hence, in accordance with the requirements of 37 C.F.R. 1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Applicant also makes known to the Examiner the following pending U.S. applications that have one or more common inventors and/or are commonly owned:

<b>U.S.S.N.(App. no.)</b>	<b>Filing Date</b>	<b>Docket No.</b>
09/748,748	12/26/00	17170-002001 (HEWM; 25835-4001)
10/452,851	05/30/03	17170-003001 (HEWM; 25835-4002)
10/684,178	10/10/03	17170-004001 (HEWM; 25835-4003)
10/384,172	03/05/03	
09/036,492	03/06/98	
09/079,829	03/15/98	
09//497,628	02/03/00	
09/296,481	10/02/98	
09/525,787	03/15/00	


Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. 1.56(b) exists.

Applicant : Alan D. Snow et al.  
Serial No. : 10/077,596  
Filed : February 15, 2002  
Page : 3 of 3

Attorney's Docket No.: 17170-006001  
(formerly, 25835-4005)

Applicant respectfully requests that the Examiner review the foregoing references and they be made of record in the file history of the above-captioned application.

Respectfully submitted,



---

Dale L. Rieger  
Reg. No. 43,045

Date: March 29, 2004

Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 678-5070  
Facsimile: (858) 678-5099

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17170-006001	Application No. 10/077,596
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Alan D. Snow et al.	
		Filing Date February 15, 2002	Group Art Unit 1617

X+= An English language abstract provided.

\*\*=Already provided

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AB	0 659 418 A1	06/28/95	EP				
	AC	1 014 996 B1	05/28/03	EP				
	AD	10-245342	09/14/98	JP			X+	
	AE	1-151514	06/14/89	JP				X+
	AF	00/12102	03/09/00	PCT				
	AG	00/57707	10/05/00	PCT				
	AH	01/49281	07/12/01	PCT				
	AI	01/49307	07/12/01	PCT				
	AJ	02/062422	08/15/02	PCT				
	AK	02/076381	10/03/02	PCT				
	AL	97/46664	12/11/97	PCT				
	AM	98/08381	03/05/98	PCT				
	AN	98/09653	03/12/98	PCT				
	AO	98/34646	08/13/98	PCT				
	AP	98/39653	09/11/98	PCT				
	AQ	98/51302	11/19/98	PCT				
	AR	99/09999	03/04/99	PCT				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
**	AS	"Progress Report on Alzheimers Disease," The National Institute on Aging, National Institutes of Health, 1997.
	AT	Arai et al, "Argyrophilic glial inclusions in the midbrain of patients with Parkinson's disease and diffuse Lewy body disease are immunopositive for NACP/ $\alpha$ -synuclein," <i>Neurosc. Lett.</i> 259:83-86 (1999)
**	AU	Barner et al. "Donepezil Use in Alzheimer Disease," <i>The Annals of Pharmacotherapy</i> , 32:70-77, (1998)
	AV	Baumann et al, "A simple isolation method for the major catechins in green tea using high-speed countercurrent chromatography," <i>J. Natural Prod.</i> 64:353-355, (2001)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
17170-006001Application No.  
10/077,596**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

37 CFR §1.98(b))

Applicant  
Alan D. Snow et al.Filing Date  
February 15, 2002Group Art Unit  
1617

X+= An English language abstract provided.

\*\*=Already provided

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	A	2002/0111309	08/15/02	Castillo et al.	514	12	08/22/01
	B	2002/0168753	11/14/02	Castillo et al.	435	226	11/30/01
	C	2002/0197692	12/26/02	Castillo et al.	435	184	11/02/01
	D	2003/0013648	01/16/03	Castillo et al.	514	12	09/24/01
	E	2003/0017998	01/23/03	Snow et al.	514	27	02/15/02
**	F	4,844,901	07/04/89	Keplinger et al.	424	195.1	05/16/88
**	G	4,940,725	07/10/90	Keplinger et al.	514	411	04/03/89
**	H	5,166,139	11/24/92	Bombardelli et al.	514	26	01/18/91
**	I	5,302,611	04/12/94	Keplinger et al.	514	411	09/30/92
	J	5,643,562	07/01/97	Kisilevsky et al.	424	78.31	03/15/95
	K	5,767,126	06/16/98	Marchbanks	514	297	10/18/94
	L	5,681,569	10/28/97	Kuznicki et al.	424	195	11/06/95
	M	5,869,469	02/09/99	Szarek	514	120	08/18/97
	N	5,958,883	09/28/99	Snow	514	16	06/05/95
	O	5,972,956	10/26/99	Hays et al.	514	297	04/29/98
	P	5,981,168	11/09/99	Reiner	435	4	05/15/98
	Q	6,037,327	03/14/00	Castillo et al.	514	23	08/28/98
**	R	6,039,949	03/21/00	Pero	424	195.1,	02/27/97
	S	6,165,912	12/26/00	McConnell et al.	438	758	09/14/99
	T	6,207,842	03/27/01	Romanczyk et al.	549	399	10/09/97
	U	6,264,994	07/24/01	Castillo et al.	424	725	12/08/98
	V	6,297,281	10/02/01	de Lassauniere et al.	514	589	03/02/99
	W	6,340,783	01/22/02	Snow	800	12	10/03/96
**	X	6,346,280.	02/12/02	Castillo et al	424	725	11/24/98
	Y	6,432,636	08/13/02	Maresh et al.	435	6	08/26/97
	Z	6,563,016	05/13/03	Snow et al.	800	12	03/27/00
	AA	6,607,758	08/19/03	Castillo et al.	424	769	08/24/01

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17170-006001	Application No. 10/077,596
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Alan D. Snow et al.	
		Filing Date February 15, 2002	Group Art Unit 1617

X+= An English language abstract provided.

\*\*=Already provided

**	AW	Benson et al. "Serum Amyloid a Protein in Amyloidosis, Rheumatic, and Neoplastic Diseases," <i>Arthritis and Rheumatism</i> , 22(1): 36-42, (1979)
**	AX	Braquet et al. "Ethnopharmacology and the Development of Natural PAF Antagonists as Therapeutic Agents," <i>Journal of Ethnopharmacology</i> , 32:135-139, (1991)
	AY	Calis et al, "Flavonoid, Iridoid, and Lignan Glycosides from <i>Putoria calabrica</i> ," <i>J. Nat. Prod.</i> 64:961-964, (2001)
	AZ	Castillo and Templeton, "Structure and metabolism of multiple heparan sulphate proteoglycans synthesized by the isolated rat glomerulus", <i>Biochimica et Biophysica Acta</i> , 1136:119-128 (1992)
	BA	Castillo and Templeton, "Subunit structure of bovine ESF (extracellular-matrix stabilizing factor(s)) A chondroitin sulfate proteoglycan with homology to human Iai (inter- $\alpha$ -trypsin inhibitors," <i>FEBS</i> , 318(3): 292-296 (1993)
**	BB	Castillo et al. "Sulfate content and specific glycosaminoglycan backbone of perlecan are critical of perlecan's enhancement of islet amyloid polypeptide (Amylin) Fibril formation." <i>Diabetes</i> , 47: 612-620, (1998).
	BC	Castillo et al., "Laminin inhibition of beta-amyloid protein (A beta) fibrillogenesis and identification of an A beta binding site localized to the globular domain repeat on the laminin a chain", <i>J. Neurosci. Res.</i> , 62(3):451-462 (2000)
	BD	Castillo et al., "The sulfate moieties of glycosaminoglycans are critical for the enhancement beta-amyloid protein fibril formation", <i>J. Neurochem.</i> , 72(4):1681-1687 (1999)
**	BE	Castillo. "Novel Purification and detailed characterization of perlecan isolated from the engelbreth-holm-swarm tumor for use in an animal model of fibrillar AB amyloid persistence in brain." <i>J. Biochem.</i> 120(2):433-444, (1996).
**	BF	Castillo. "Perlecan Binds to the $\beta$ -amyloid proteins (A $\beta$ ) of alzheimer's disease, Accelerates A $\beta$ fibril formation, and Maintains A $\beta$ fibril Stability." <i>Journal of Neurochemistry</i> , 69( 6): 2452-2465, (1997).
	BG	Clark et al, "Islet Amyloid, Increased A-Cells, Reduced B-Cells and Exocrine Fibrosis: Quantitative Changes in The Pancreas in Type 2 Diabetes," <i>Diabetes Res.</i> 9:151-159, (1988)
	BH	Conway et al., "Accelerated <i>in vitro</i> fibril formation by a mutant $\alpha$ -synuclein linked to early-onset Parkinson disease," <i>Nature Med.</i> 4:1318-1320, (1998)
**	BI	Cooper et al. "Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients." <i>Proc. Natl. Acad. Sci. USA</i> , 84:8629-8632, (1987)
	BJ	Crutcher et al., "Cellular and molecular pathology in Alzheimer's disease", <i>Hippocampus</i> , 3:271-287 (1993)
**	BK	Cutler et al. "Correspondence: Tacrine in Alzheimers Disease," <i>The New England Journal of Medicine</i> , pp. 808-810, (Mar. 18, 1993.)
	BL	Czochanska et al, "Direct Proof of a Homogeneous Polyflavan-3-ol Structure for Polymeric Proanthocyanidins," <i>J.C. S. Chem. Comm.</i> pp. 375-377, (1979)
	BM	Derwent Abstract, Accession Number 7950380 citing JP 1151514 published June 14, 1989, "Compsns. For treating and preventing nervous diseases - contains carboxylic acid, pref. gallic or pyrogallol-4-carboxylic acid, esp. useful fro alzheimers disease - contains carboxylic acid, pref. gallic or pyrogallol-4-carboxylic acid, esp. useful for alzheimers disease."
	BN	Ferreira et al, "Tetrahedron Report Number 308: Diversity of Structure and Function in Oligomeric Flavanoid," <i>Tetrahedron</i> 48:1743-1803, (1992)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17170-006001	Application No. 10/077,596
<b>Information Disclosure Statement</b> <b>by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Alan D. Snow et al.	
		Filing Date February 15, 2002	Group Art Unit 1617

X+= An English language abstract provided

\*\*=Already provided

	BO	Fletcher et al, "Plant Proanthocyanidins. Part 3. Conformational and Configurational Studies of Natural Procyanidins," <i>JCS Perkin</i> 1:1628-1637, (1977)
**	BP	Flood et al. "Amnestic effects in mice of four synthetic peptides homologous to amyloid B protein from patients wit alzheimer disease." <i>Proc. Natl. Acad. Sci. USA</i> , 88:3363-3366 (1991)
**	BQ	Flood et al. "An amyloid $\beta$ -protein fragment, A $\beta$ [12-18], equipotently impairs post-training memory processing when injected into different limbic system structures." <i>Brain Research</i> 663:271-276 (1994).
	BR	Fraser et al., "Conformation and fibrillogenesis of Alzheimer A beta peptides with selected substitution of charged residues", <i>J. Mol. Biol.</i> , 244(1):64-73 (1994)
	BS	Fukuchi et al., "Increased expression of beta-amyloid protein precursor and microtubule-associated protein tau during the differentiation of murine embryonal carcinoma cells", <i>J. Neurochem.</i> , 58(5):1863-1873 (1992)
**	BT	Games et al. "Alzheimer-type neuropathology in transgenic mice overexpressing V717F B-amyloid precursor protein." <i>Nature</i> , 373: 523-527 (1995)
**	BU	Gejyo et al. "A New Form of Protein Associated with Chronic Hemodialysis was Identified as B2 Metroglobulin," <i>Biochemical and Biophysical Research Communications</i> , 129(3): 701-706, (1985).
**	BV	Gejyo et al. " $\beta$ 2-Metroglobulin: A New Form of Protein Associated with Chronic Hemodialysis," <i>Kidney International</i> , 30:385-590 (1986).
**	BW	Glenner et al. "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <i>Biochemical and Biophysical Research Communications</i> , 120(3): 885-890 (1984)
**	BX	Grundke-Iqbal et al. "Abnormal Phosphorylation of the Microtubule-Associated Protein Tau Alzheimer Cytoskeletal Pathology," <i>Proc. Natl. Acad. Sci. USA</i> , 83:4913-4917 (1986)
	BY	Gujer et al, "Glucosylated Flavonoids and Other Phenolic Compounds From Sorghum," <i>Phytochemistry</i> 25:1431-1436 (1986)
**	BZ	Haass et al. "The swedish mutation causes early-onset alzheimer's disease by $\beta$ -secretase cleavage with in the secretory pathway." <i>Nature Medicine</i> 1(12):1291-1296 (1995).
**	CA	Harada et al. "Human Amyloid Protein: Chemical Variability and Homogeneity," <i>Journal of Histochemistry and Cytochemistry</i> , 19(1): 1-15 (1970)
	CB	Hardy et al., "Framing $\beta$ -amyloid", <i>Nature Genet.</i> , 1:233-234 (1992)
**	CC	Harrigan et al. "Beta Amyloid is Neurotoxic in Hippocampal Slice Cultures," <i>The Neurobiology of Aging</i> , 16(5): 779-789, (1995)
	CD	Hart et al., "Overproduction of perlecan core protein in cultured cells and transgenic mice", <i>J. Pathol.</i> , 194(2):262-269 (2001)
	CE	Hashimoto et al., "Human recombinant NACP/ $\alpha$ -synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease," <i>Brain Res.</i> 799:301-306, (1998)
	CF	Hertel et al., "Inhibition of the electrostatic interaction between $\beta$ -amyloid peptide and membranes prevents $\beta$ -amyloid-induced toxicity," <i>Proc. Natl. Acad. Sci. USA</i> 94: 9412-9416 (1997)
	CG	Hemingway et al, "Linkage Isomerism in Trimeric and Polymeric 2,3- <i>cis</i> -Procyanidins," <i>J. Chem. Soc. Perkins Trans.</i> 1:1209-1216 (1982)
**	CH	Ho et al. "Phytochemicals in Teas and Rosemary and Their Cancer-Preventive Properties," <i>ACS Symp. Ser. (Food Phytochemicals for Cancer Prevention II)</i> vol. 547, pp. 2-19 1994.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17170-006001	Application No. 10/077,596
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Alan D. Snow et al.	
		Filing Date February 15, 2002	Group Art Unit 1617
(37 CFR §1.98(b))			

X+= An English language abstract provided.

\*\*=Already provided

**	CI	Hsiao et al. "Age-related CNS Disorder and early death in transgenic FVB/N mice overexpressing alzheimer amyloid precursor proteins." <i>Neuron</i> , vol. 15, 1203-1218, Nov., 1995.
**	CJ	Husby et al. "Nomenclature of Amyloid and Amyloidosis," <i>Bulletin of the World Health Organization</i> , 71(1):105-108, (1993)
	CK	Ishimaru et al. "Flavan-2-ol and Procyanidin Glycosides from <i>Quercus Miyagii</i> ," <i>Phytochemistry</i> 26:1167-1170, (1987)
**	CL	Jain et al. "Antiinflammatory Effects of an Ayurvedic Preparation, Brahmi Rasayan, in Rodents," <i>Indian Journal of Experimental Biology</i> , 32:633-636 (1994)
**	CM	Johnson et al. "Islet Amyloid Polypeptide: Mechanisms of Amyloidogenesis in the Pancreatic Islet and Potential Roles in Diabetes Mellitus," <i>Laboratory Investigation</i> , 66(5): 522-534, (1992)
**	CN	Johnson et al. "Islet Amyloid, Islet-Amyloid Polypeptide, and Diabetes Mellitus," <i>The New England Journal of Medicine</i> , 321(8): 513-518, (1989)
	CO	Jones et al, "The Condensed Tannins of Pasture Legume Species," <i>Photochemistry</i> , 15:1407-1409 (1976)
	CP	Jucker et al., "Age-related deposition of glia-associated fibrillar material in brains of C57BL/6 mice", <i>Neuroscience</i> , 60(4):875-889 (1994)
**	CQ	Kamei et al. "Amyloidosis Associated with Juvenile Rheumatoid Arthritis," <i>Acta Pathol. Jpn.</i> , 32(1):23-33 (1982)
	CR	Kashiwada et al, "Tannins and Related Compounds. XCIII. <sup>1)</sup> Occurrence of Enantiomeric Proanthocyanidins in the Leguminosae Plants, <i>Cassia fistula</i> L. and <i>C.javanica</i> L.," <i>Chem. Pharm. Bull.</i> 38:888-893 (1990)
	CS	Kim et al, "Neuroprotective Constituents from <i>Hedyotis diffusa</i> ," <i>J. Nat. Prods.</i> 64:75-78, (2001)
**	CT	Kitaguchi et al. "Novel Precursor of Alzheimer's Disease Amyloid Protein Shows Protease Inhibitory Activity," <i>Nature</i> , 331:530-532, (1988)
**	CU	Kosik et al. "Microtubule--Associated Protein Tau is a Major Antigenic Component of Paired Helicule Filaments in Alzheimer's Disease," <i>Proc. Natl. Acad. Sci. USA</i> , 83:4044-4048 (1986)
	CV	Krüger et al., "Ala30Pro mutation in the gene encoding $\alpha$ -synuclein in Parkinson's disease," <i>Nature Genet.</i> 18:106-108, (1998)
	CW	Latimer et al. "71. Inhibitors of Amyloid- $\beta$ Aggregation: Dimeric Catechols Inhibit Aggregation and Deposition of A $\beta$ ," American Chemical Society 221 <sup>st</sup> National Meeting, San Diego, CA April 1-5, 2001 (MEDI 071) [posted on 03/23/01]
**	CX	Lee et al. "A68: A Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau," <i>Science</i> , 251: 675-678, (1991)
**	CY	Levine. "Thioflavine T interaction with synthetic alzheimer's disease B-amyloid peptides: Detection of amyloid aggregation in solution." <i>Protein Science</i> , 2:404-410, (1993)
**	CZ	Levine. "Thioflavine T interacton with amyloid B-sheet structures." <i>Amyloid: Int. J. Exp. Clin. Invest.</i> 2:1-6, (1995)
	DA	Lorenzo et al, "Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus," <i>Nature</i> 368:756-760, (1994)
**	DB	Mandybur et al. "Cerebral Amyloid Angiopathy: The Vascular Pathology and Complications," <i>Journal of Neuropathology and Experimental Neurology</i> , 45(1): 79-90, (1986).

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17170-006001	Application No. 10/077,596
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Alan D. Snow et al.	
		Filing Date February 15, 2002	Group Art Unit 1617

X+= An English language abstract provided.

\*\*=Already provided

	DC	Maresh et al., "Detection and quantitation of perlecan mRNA levels in Alzheimer's disease a normal aged hippocampus by competitive reverse transcription-polymerase chain reaction", <i>J. Neurochem.</i> , 67(3):1132-1144 (1996)
**	DD	Masters et al. "Amyloid Plaque Core Protein in Alzheimers Disease and Down Syndrome," <i>Proc. Natl. Acad. Sci. USA</i> 82:4245-4249 (1983)
	DE	Matthews et al, "Method for estimation of Proanthocyanidins based on their acid depolymerization in the presence of nucleophiles," <i>J. Agric. Food Chem.</i> 45:1195-1201, (1997)
	DF	Mattice et al, "Molecular weight averages and <sup>13</sup> C NMR intensities provide evidence for branching in proanthocyanidin polymers," <i>Phytochem.</i> 23(6):1309-1311, (1984)
**	DG	McAdam et al. "Association of Amyloidosis with Erythema Nodosum Leprosum Reactions and Recurrent Neutrophil Leucocytosis in Leprosy," <i>The Lancet</i> , pp. 572-576, Sep. 27, 1975.
**	DH	Metaxas et al. "Familial Mediterranean Fever and Amyloidosis," <i>Kidney International</i> , 20:676-685, (1981)
	DI	Miller et al., "Localization of perlecan (or a perlecan-related macromolecule) to isolated microglia in vitro and to microglia/macrophages following infusion of beta-amyloid protein into rodent hippocampus", <i>Gila</i> , 21(2):228-243 (1997)
	DJ	Morimoto et al, "Tannins and Related Compounds. LXI. <sup>1)</sup> Isolation and Structure of Novel Bi- and Triflavanoids from the leaves of <i>Cassia fistula</i> L.," <i>Chem. Pharma. Bull.</i> 36:39-47, (1988)
**	DK	Murrell et al. "A mutation in the amyloid precursor protein associated with hereditary alzheimer's disease." <i>Science</i> , 254: 97-99 (1991)
	DL	Nahri et al. "Both familial Parkinson's disease mutations accelerate $\alpha$ -Synuclein aggregation," <i>J. Biol. Chem.</i> 274:9843-9846 (1999)
**	DM	Naiki et al. "Kinetic analysis of amyloid Fibril polymerization <i>in vitro</i> ." <i>Laboratory Investigation</i> , 65(1):104-110, (1991)
**	DN	Naiki, H. and K. Nakakuki, "First-order kinetic model of Alzheimer's $\beta$ -amyloid fibril extension in vitro," <i>Laboratory investigation</i> , 74(2):374-383 (1996)
	DO	Niwano et al., "Inhibitory action of amyloid precursor protein against human Hageman factor (factor XII)," <i>J. Lab. Clin. Med.</i> 125:251-6 (1995)
	DP	Nonaka et al, "Tannins and Related Compound. XV. <sup>1)</sup> A New Class of Dimeric Flavan-3-ol Gallates, Theasinensins A and B, and Proanthocyanidin Gallates from Green Tea Leaf. (1)," <i>Chem. Pharm. Bull.</i> 31:3906-3914, (1983)
**	DQ	Pardridge et al. "Amyloid Angiopathy of Alzheimer's Disease: Amino Acid Composition and Partial Sequence of a 4,200-Dalton Peptid Isolated from Cortical Microvessels," <i>Journal of Neurochemistry</i> , 49(5): 1394-1401, (1987)
	DR	Patent Abstracts of Japan citing Japanese Patent 10-245342 published September 14, 1998, "Agent for reducing neural toxicity of beta-amyloid protein"
**	DS	Pike et al. "In Vitro Aging of $\beta$ -Amyloid Protein Cause Peptide Aggregation and Neurotoxicity," <i>Brain Research</i> , 563:311-314, (1991)
**	DT	Pike et al. "Structure-Activity Analyses of $\beta$ -Amyloid Peptides: Contributions of the $\beta$ 25-35 Region to Aggregation and Neurotoxicity," <i>Journal of Neurochemistry</i> , 64(1): 253-265, (1995)
**	DU	Ponte et al. "A New A4 Amyloid mRNA Contains a Domain Homologous to Serine Proteinase Inhibitors," <i>Nature</i> , 311:525-527, (1988)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17170-006001	Application No. 10/077,596
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Alan D. Snow et al.	
		Filing Date February 15, 2002	Group Art Unit 1617

X+= An English language abstract provided

\*\*=Already provided

	DV	Porter et al, "Isolation of three naturally occurring O-β-glucopyranosides of procyanidin polymers," <i>Phytochemistry</i> 24:567-569, (1985)
	DW	Porter, L.J, "Flavans and proanthocyanidins," Chapter 2 in <i>Flavans and proanthocyanidins--Advances in Research since 1986</i> , J B Harborne (Ed.) London: Chapman and Hall pp. 23-55, 1994
	DX	Porter, J.J, "Flavans and proanthocyanidins," Chapter 2 in <i>The Flavanoids--Advances in Research since 1980</i> , J B Harborne (Ed.), London: Chapman and Hall, pp. 21-62, 1988
	DY	Prieur et al, "Oligomeric and polymeric procyanidins from grape seeds," <i>Phytochem.</i> 36:781-784, 1994
	EA	Rogers et al., "Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study", <i>Eur. Neuropsychopharmacol.</i> , 8:67-75 (1998)
	EB	Sang et al, "Iridoid Glycosides from the leaves of <i>Morinda citrifolia</i> ," <i>J. Nat. Prod.</i> 64:799-800 (2001)
	EC	Santos-Buelga, C. and A. Scalbert, "Proanthocyanidins and tannin-like compounds – nature, occurrence, dietary intake and effects on nutrition and health," <i>J. Sci.. Food Agri.</i> 80: 1094-1117, (2000)
**	ED	Saraiva et al. "Amyloid Fibril Protein in Familial Amyloidotic Polyneurotherapy, Portugese Type," <i>J. Clin. Invest.</i> 74:104-119 (1984)
**	EE	Saraiva et al. "Studies on Plasma Transthyretin (Prealbumin) in Familial Amyloidotic Polyneuropathy, Portugese Type," <i>J. Lab. Clin. Med.</i> 102(4): 590-603, (1983)
	EF	Sekiguchi et al., "Characterization of proteoglycans synthesized by murine embryonal carcinoma cells (P19) reveals increased expression of perlecan (heparan sulfate proteoglycan) during neuronal differentiation", <i>J. Neurosci. Res.</i> , 38(6):670-686 (1994)
**	EG	Skinner et al. "The Prealbumin Nature of the Amyloid Protein in Familial Amyloid Polyneuropathy (FAP)-Swedish Variety," <i>Biochemical and Biophysical Research Communications</i> , 99(4):1326-1332, (1981)
	EH	Snow et al., "An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar Aβ-amyloid in rat brain", <i>Neuron.</i> , 12(1):219-234 (1994)
	EI	Snow et al., "Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease", <i>Arch. Biochem. Biophys.</i> , 320(1):84-95 (1995)
	EJ	Snow et al., "Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain", <i>Am. J. Pathol.</i> , 144(2):337-347 (1994)
	EK	Snow et al., "Identification in immunolocalization of a new class of proteoglycan (keratan sulfate) to the neuritic plaques of Alzheimer's disease", <i>Exp. Neurol.</i> , 138(2):305-317 (1996)
	EL	Snow et al., "In vitro and in vivo models to unravel the potential roles of Flavans and β/A4 in the pathogenesis of Alzheimer's disease", <i>Hippocampus</i> , 3(Special Issue):257-268 (1993)
	EM	Snow et al., "Peripheral distribution of dermatan sulfate proteoglycans (decorin) in amyloid containing plaques and their presence in neurofibrillary tangles of Alzheimer's disease", <i>J. Histochem Cytochem.</i> , 40(1):105-113 (1992)
**	EN	Snow. "Proteoglycans in the pathogenesis of alzheimer's disease and other amyloidoses." <i>Neurobiology of Aging</i> , 10:481-497, (1989)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17170-006001	Application No. 10/077,596
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Alan D. Snow et al.	
		Filing Date February 15, 2002	Group Art Unit 1617

X+= An English language abstract provided

\*\*=Already provided

	EO	Spillantini et al., "α-Synuclein in filamentous inclusions in Lewy bodies from Parkinson's disease and dementia with Lewy bodies," <i>Proc. Natl. Acad. Sci. USA</i> . 95:6469-6473 (1998)
	EP	Stappenbeck et al., "80. Inhibitors of Amyloid-β Aggregation: Histidine Residues in Aβ Play a Crucial Role in Aggregation," American Chemical Society 221 <sup>st</sup> National Meeting, San Diego, CA April 1-5, 2001 (MEDI 080) [posted on 03/23/01]
**	EQ	Steinberg. "Uncaria Tomentosa (cat's Claw) A wondrous herb from the peruvian rain forest." <i>Townsend Letter for Doctors</i> -pp. 442-443, may 1994.
**	ER	Tamaoka et al. "Amyloid B protein 1-42/43(AB 1-42/43) in crebellar diffuse plaques: enzyme-linked immunosorbent assay and immunocytochemical study." <i>Brain Research</i> 67:151-156 (1995)
**	ES	Tamaoka et al. "Biochemical evidence for the long tail form of amyloid B protein as a seed molecule in cerebral deposits of alzheimer's disease." <i>Biochemical and biophysical research communications</i> , 205(1): 834-842, (1994)
**	ET	Tanzi et al. "Protein Inhibitor Domain Encoded by an Amyloid Protein Precursor mRNA Associated with Alzheimer's Disease," <i>Nature</i> , 331:528-532, (1988)
**	EU	Tawara et al. "Amyloid Fibril Protein in Type 1 Familial Amyloidotic Polyneurotherapy in Japanese," <i>J. Lab. Clin. Med.</i> , 98(6): 811-822, (1981)
	EV	Thompson et al., "Plant Proanthocyanidins. Part 1. Introduction; the Isolation, Structure, and Distribution in Nature of Plant Procyranidins," <i>J. Chem. Soc. Perkins Trans.</i> 1: 1387-1399 (1972)
	EW	Tückmantel, "Studies in Polyphenol Chemistry and Bioactivity. 1. Preparation of Building Blocks from (+)-Catechin. Procyanidin Formation. Synthesis of the Cancer Cell Growth Inhibitor, 3-O-Galloyl-(2R,3R)-epicatechin-4β,8-[3-O-Galloyl-(2R,3R)-epicatechin]," <i>J. Am. Chem. Soc.</i> 121:12073-12081 (1999)
**	EX	Van Broeckhoven et al. "Amyloid β Protein precursor gene and Hereditary cerebral hemorrhage with amyloidosis (Dutch)." <i>Science</i> , 248:1120-1122 (1990)
**	EY	Wirth et al. "Pharmacologically active procyanidines from the bark of Uncaria tomentosa." <i>Phytomedicine</i> , vol. 4 (3), pp. 265-266, 1997.
	EZ	Wood et al., "α-synuclein fibrillogenesis is nucleation-dependent," <i>J. Biol. Chem.</i> 274:19509-19512, (1999)
	FA	Zhang et al., "Potentillanin, A Biflavanoid and a procyanidin glycoside from potentilla viscosa," <i>Phytochemistry</i> 27:3277-3280, (1988)
	FB	English Language Translation of Japanese Patent 10-245342.
	FC	Hashimoto et al., "Tannins and related Compounds. XC. 8-C-Ascorbyl (-) -Epigallocatechin 3-)-Gallate and novel dimeric Flavan-3-ols, Oolonghomobisflavans A and B from Oolong tea," <i>Chem Pharm. Bull.</i> 37(12) 3255-3263 (1989)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	